Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05629442 · ClinicalTrials.gov registry record
ctDNA and Organ Preservation/Pathologic CR in Rectal Cancer
A clinical trial, sponsored by Massachusetts General Hospital.
- Not yet
- Registry status
- 60
- Enrollment target
NCT05629442: Clinical Trial study, sponsored by Massachusetts General Hospital.
NCT05629442 is a clinical trial that has not yet begun recruiting, run by Massachusetts General Hospital. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05629442 has not yet begun recruiting, sponsored by Massachusetts General Hospital.
- NOT YET RECRUITING
- Registry status
- 60 participants
- Enrollment target
Study Summary
This prospective observational, non-therapeutic study for patients with T3, T4, or node positive rectal cancer eligible to undergo total neoadjuvant therapy. This research study involves the collection of data and biospecimens (blood and tissue) to see if the presence of circulating tumor DNA (genetic material) ctDNA will help monitor rectal cancer more closely and potentially detect a recurrence before routine scans, performed per standard of care C2i Genomics, a biotechnology company, and the Spier Foundation are supporting this research study by providing funding for the study.
Interventions
- OTHER ctDNA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-10-01 |
| Est. Completion | 2030-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05629442
The ClinicalTrials.gov registry entry for NCT05629442 describes a study currently listed as not yet recruiting, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ctDNA is the first listed.
NCT05629442 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05629442 about?
NCT05629442 is a clinical study titled "ctDNA and Organ Preservation/Pathologic CR in Rectal Cancer". This prospective observational, non-therapeutic study for patients with T3, T4, or node positive rectal cancer eligible to undergo total neoadjuvant therapy. This research study involves the collection of data and biospecimens (blood and tissue) to see if the presence of circulating tumor DNA (gene...
What is the current status of trial NCT05629442?
This trial is currently not yet recruiting. The enrollment target is 60 participants. The study started on 2026-10-01. Estimated completion is 2030-06.
What interventions are being tested in trial NCT05629442?
The interventions under investigation include: ctDNA (OTHER).
Who is sponsoring clinical trial NCT05629442?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.